Figure 7.

Parthenolide treatment inhibits AR expression, PSA secretion and tumor growth in ADRPC. A: Inhibition on AR transcription in CWR22Rv1 cells treated with parthenolide. AR mRNA levels measured using real-time RT-PCR. CWR22Rv1 cells (50% to 60% confluent) were treated with parthenolide (0, 2, 5, and 10 μg/ml) for 6 hours in RPMI 1640 supplemented with 10% FBS. B: Parthenolide significantly inhibited AR expression in CWR22Rv1 cells in a dose-dependent manner. C: AR mRNA in CWR22Rv1 cells in mice treated with parthenolide. CWR22Rv1 cells were implanted in female mice (four mice per group) 6 days before drug treatment. The mice were treated with solvent control or parthenolide alone (QDx5/week at 40 mg/kg daily). At the end of day 35, mice were sacrificed and tissues were collected for RNA extraction and RT-PCR. TBP was used as internal control. Expression of AR was normalized to TBP in each sample. D: AR protein level in mice tumors treated with parthenolide. Mice tissues were collected for protein extraction and Western blot analysis. E: Parthenolide inhibits serum PSA level in mouse xenograft model. Mouse blood was collected for measurement of PSA levels using enzyme-linked immunosorbent assay method. F: Parthenolide inhibits tumor growth in tumor model. Body weight and tumor volume were measured twice weekly in three dimensions using calipers. The data represent means ± SD from all of the mice included in this experiment. *P < 0.05.